11:41 AM EST - Valeant Pharmaceuticals International, Inc. : announced today that the U.S. Federal Trade Commission (FTC) has completed its review of the proposed acquisition of Medicis Pharmaceutical Corporation by Valeant and has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) without conditions. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading up $1.61 at $55.04.
